Mar 27, 2015 at 09:44 | Source: PTI
Financial details of the transaction are not known. Zydus BSV Pharma develops, manufactures and markets non-infringing and proprietary novel drug delivery system (NDDS) of approved anti-cancer agents for global markets.
Mar 12, 2015 at 17:47 | Source: PTI
Apart from Europe, Ochoa Laboratories currently has operations in Uganda, Venezuala and Costa Rica among other Latin American and African countries. Dr Datsons Labs shares were trading 2.99 percent down at Rs 7.80 apiece during pre-close session on the BSE.
Feb 12, 2015 at 20:56 | Source: PTI
"Pursuant to the global deal, the company will have its distribution rights terminated for the oncology portfolio in return for accessing the distribution rights of the acquired vaccines portfolio," GlaxoSmithKline Pharmaceuticals Ltd said in a filing to the BSE.
Dec 23, 2014 at 20:21 | Source: PTI
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.
Oct 31, 2014 at 11:01 | Source: PTI
An international organisation working for cancer affected people has asked the Obama administration not to pressurise India to reject a compulsory license on a drug for a rare form of leukaemia which would be a de facto endorsement of an excessive price.
Sep 04, 2014 at 12:22 | Source: Moneycontrol.com
Venus Remedies has recently entered into a collaborative agreement with TEVA for a block buster Anti Cancer drug.
Aug 27, 2014 at 13:43 | Source: Moneycontrol.com
Venus Remedies will be initially manufacturing the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations.
Aug 20, 2014 at 13:40 | Source: Moneycontrol.com
"Venus has achieved yet another landmark by receiving its first marketing authorisation in Switzerland from Swiss drug authority (SWISSMEDIC) for Gemcitabine 200 mg and 1 g injection through Venus Pharma GmbH, the German subsidiary," said the company in its filing.
Aug 20, 2014 at 11:29 | Source: Moneycontrol.com
GBR 1302 was discovered and developed by Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland and would be first molecule to could become a patented molecule or drug for the company once it goes through multiple stages of research and development.
Aug 20, 2014 at 11:23 | Source: CNBC-TV18
GBR 1302 molecule is a genetically engineered molecule and will be used for the study of breast cancer, says Michael Buschle.